Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

4 Citations (Scopus)

19 Downloads (Pure)

Original language	English
Pages (from-to)	11
Journal	EJNMMI Radiopharmacy and Chemistry
Volume	2
Issue number	1
DOIs	https://doi.org/10.1186/s41181-017-0030-z
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{1f231e289b5f44fd853a8761851e2a90,

title = "Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?",

author = "Dalm, \{Simone U\} and \{de Jong\}, Marion",

year = "2017",

doi = "10.1186/s41181-017-0030-z",

language = "English",

volume = "2",

pages = "11",

journal = "EJNMMI Radiopharmacy and Chemistry",

issn = "2365-421X",

publisher = "Springer Science+Business Media",

number = "1",

}

TY - JOUR

T1 - Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer

T2 - does the model choice influence the outcome?

AU - Dalm, Simone U

AU - de Jong, Marion

PY - 2017

Y1 - 2017

U2 - 10.1186/s41181-017-0030-z

DO - 10.1186/s41181-017-0030-z

M3 - Comment/Letter to the editor

C2 - 29503852

SN - 2365-421X

VL - 2

SP - 11

JO - EJNMMI Radiopharmacy and Chemistry

JF - EJNMMI Radiopharmacy and Chemistry

IS - 1

ER -